

ASAS classification criteria for axial spondyloarthritis: a look at the unfilled part of the glass

Sirs,

The concept of “spondylitic disease without radiographic evidence of sacroiliitis” was first published in 1985 (1), and was more recently redefined as “non-radiographic axial spondyloarthritis (nr-axSpA)”, while the term ankylosing spondylitis (AS) is considered to be synonymous with the presence of radiographic sacroiliitis in a patient with axial spondyloarthritis” (axSpA) (1, 2). This has led to the new Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA as a disease entity that encompasses patients with AS, and also those that may or may not show evidence of sacroiliitis on MRI (but not on pelvic radiography) (3). So a patient with chronic back pain with age at onset of <45 years can be classified as having axSpA if the “imaging arm” (the presence of sacroiliitis as detected by either x-ray or by MRI plus ≥1 SpA feature(s)) or the “clinical arm” (the presence of HLA-B27 plus ≥2 SpA features and the imaging arm) features are fulfilled.

The primary objective of all classification criteria is to identify a homogeneous patient population for basic research and clinical trials. Therefore, the patients so selected must be equivalent in terms of demographics, clinical characteristics, treatment response and prognosis. A comparison of the patient sub-populations [defined by the two different subgroups of axSpA (AS vs. nr-axSpA), as well as those within the nr-axSpA (clinical arm vs. imaging-MRI only)] is needed to validate these components of the ASAS criteria.

There has been some recent debate on the similarities and differences between AS and nr-axSpA. It has been suggested that nr-axSpA and AS are different, though overlapping, entities, based on female predominance, weaker association with HLA-B27, greater diversity with regard to disease progression, and lower response to treatment in the nr-axSpA group (4). However, another recent publication reached an opposite conclusion, claiming that nr-axSpA is the same entity as AS, but with a self-limiting or a slower disease progression, possibly due to female predominance and lower inflammatory response (5). But both of these publications acknowledged the presence of

Table I. Composition of patient populations in recent trials of TNF inhibitors for axSpA.

	ABILITY-1 n=185	RAPID-axSpA n=325	Etanercept n=215	INFAST n=156
Anti-TNF agent	Adalimumab	Certolizumab	Etanercept	Infliximab
Target population	Nr-axSpA	axSpA	Nr-axSpA	axSpA-Imaging arm
Trial specific Inclusion criteria ¹	None	Presence of MRI lesions or high CRP	Disease duration <5 yrs	Disease duration <3 yrs NSAID naïve ⁴
Clinical arm ²	51%	20% (46%) ³	19%	0%
Imaging-nraxSpA	49%	25% (54%) ³	81%	40%
Imaging-AS	0%	55%	0%	60%

¹ Those not used in pivotal registration trials of anti-TNF agents for AS; ² Many patients in the clinical arm had an unknown MRI status; ³ Percentage in the nr-axSpA group only; ⁴ NSAIDs not previously used or used in submaximal doses.

Table II. Some patient characteristics in recent trials of TNF inhibitors for axSpA.

	ABILITY-1	RAPID-axSpA ¹	Etanercept	INFAST
Age, mean (yrs)	38	37.4	32	31.4
Male gender	46%	48%	61%	72%
HLA-B27 positivity	78%	75%	72%	86%
Symptom duration mean (yrs)	10.1	5.5 ²	2.4	1.8
CRP mean (mg/dl)	7.2	11.9 ²	6.6	1.9

¹ The data shown are for the nr-axSpA subgroup only; ² Median value.

Table III. Prevalence of HLA-B27 among patients in different subgroups of axSpA in recent trials of TNF inhibitors for nr-axSpA.

	ABILITY-1	RAPID-axSpA	Etanercept	INFAST
Nr-axSpA (Imaging arm)	58%	54% ¹	66%	NR
AS	NA	82%	NA	NR
All axSpA	78%	79%	72%	86%

¹ Many patients in the clinical arm had an unknown MRI status; NA: not applicable; NR: not reported.

greater heterogeneity among the patients with nr-axSpA.

Recent data from DESIR cohort (6) suggest that patients in the clinical arm of the ASAS criteria for axSpA may account for some of the reported differences between nr-axSpA and AS (7). Despite similarities in many clinical variables, the patients in the imaging arm of the ASAS criteria for axSpA were significantly younger (30.6 vs. 32.6 years), more frequently male (59.2% vs. 41.6%) and had higher mean CRP levels (11.6 mg/dl vs. 5.2 mg/dl), when compared with those in the clinical arm. On analysing patients within the imaging arm, those with only positive MRI also had a higher male prevalence (56.2%) and mean CRP levels (10.5 mg/dl) than those in the clinical arm.

A study of another cohort (SPACE) assessed the prevalence of structural lesions on MRI among patients with early

axSpA, and those with possible or no SpA (8, 9). The prevalence of any type of MRI-spine lesions (fatty changes, erosion or syndesmophyte) in the patients meeting the clinical arm was very similar to those with possible or no SpA, but lower than those observed in the AS patients or nr-axSpA patients in the imaging arm (8). MRI lesions in the sacroiliac joints (fatty lesion, sclerosis, erosions or ankylosis) were also less common in the clinical arm as compared to each subgroup of the imaging arm (9). These results obtained in an early axSpA cohort are of interest as they depict the differences between the two arms of the nr-axSpA with regard to the structural MRI lesions in the axial skeleton at an early symptom stage. Nr-axSpA patients belonging to the two arms of the ASAS criteria for axSpA, may also differ in their natural history. A recent retrospective analysis of patients

who had presented with inflammatory back pain and possible early AS, reported that after 5–10 years of follow-up 87.5% of patients with sacroiliitis on MRI at baseline developed grade II or higher sacroiliitis, compared to only 30% in those with no sacroiliitis on MRI (10). This is in line with some other studies indicating an association of baseline MRI findings with future development of radiographic sacroiliitis (11, 12).

Limited evidence suggests that the two subgroups of nr-axSpA may also differ in their response to anti-TNF therapy. In the ABILITY-1 trial of adalimumab, which included nr-axSpA patients, there was a trend for a higher response in patients with a baseline MRI SPARCC SI joint score ≥ 2 than in those with a score < 2 (11). Another study reported higher response rates to TNF inhibitors in patients with positive imaging findings than those without. However, imaging in that study included also standard radiographs and CT-scans (13).

The ASAS classification criteria for axial SpA were primarily developed to facilitate the conduct of clinical trials, especially for those in the pre-radiographic stage. To date, four randomised controlled trials have been conducted using the new classification criteria (14–17). However, they mostly targeted different subgroups of the disease using different inclusion criteria (Table I). This led to selection of heterogeneous patient populations across these four studies, which makes the comparison rather difficult (Table II). ABILITY-1 trial of adalimumab and the etanercept trial both involved patients with nr-axSpA; however the composition of their study populations were markedly different, with 49% and 81% of the patients meeting the imaging arm, respectively (Table I). In some of these studies the prevalence of HLA-B27 in the imaging arm was much lower than expected for AS (Table III). Moreover, most of these trials adopted additional inclusion criteria for patient selection, which were not used in pivotal registration trials of anti-TNF agents for the treatment of AS. This may indirectly indicate a difference in treatment response between AS and nr-axSpA, or point out the need for an increase in the specificity of the criteria set for nr-axSpA. Thus, the broad spectrum and the complex multi-arm selection design of the axSpA classification criteria may lead to different composition of patients in different trials, which may contribute to the

heterogeneity of the observed results. Criteria sets should be regarded as dynamic concepts open to modifications or updates as our knowledge advances. The clinical entity of AS is well established within the concept of axSpA, with good sensitivity and high degree of specificity, as defined by the modified New York criteria (18). Classification criteria that target a narrower clinical spectrum may better serve their primary objectives; *i.e.* to facilitate enrolment of homogenous patient populations into clinical trials, and communication within the scientific community. Until such criteria have been developed, all we have are the current classification criteria for axSpA that encompass AS and nr-axSpA. In the end, it needs to be emphasised that as yet there are no diagnostic criteria for these clinical entities.

N. AKKOÇ¹

M.A. KHAN²

¹Division of Rheumatology, Dokuz Eylül University School of Medicine İzmir, Turkey;

²Division of Rheumatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Address correspondence to:

Nurullah Akkoç, Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey.

E-mail: nurullah.akkoc@gmail.com

Reprints will not be available from the authors.

Competing interests: none declared.

References

1. KHAN MA, VAN DER LINDEN SM, KUSHNER I, VALKENBURG HA, CATS A: Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. *Arthritis Rheum* 1985; 28: 40–3.
2. RUDWALEIT M, KHAN MA, SIEPER J: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis Rheum* 2005; 52: 1000–8.
3. RUDWALEIT M, VAN DER HEIJDE D, LANDEWÉ R *et al.*: The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009; 68: 777–83.
4. ROBINSON PC, WORDSWORTH BP, REVEILLE JD, BROWN MA: Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. *Ann Rheum Dis* 2012; 72: 162–4.
5. PODOUBNY D, SIEPER J: Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Curr Opin Rheumatol* 2014; 26: 377–83.
6. MOLTO A, PATERNOTTE S, VAN DER HEIJDE D *et al.*: Evaluation of the validity of the differ-

ent arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. *Ann Rheum Dis* 2014 Jan 3 [Epub ahead of print].

7. KILTZ U, BARALIAKOS X, KARAKOSTAS P *et al.*: Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res (Hoboken)* 2012; 64: 1415–22.
8. DE HOOGE M, VAN DEN BERG R, NAVARRO-COMPAN V *et al.*: Prevalence Of Structural Lesions Seen On MRI-Spine In Patients With (Possible) Axial Spondyloarthritis (axSpA) Included In The SPACE-Cohort. *Arthritis Rheum* 2013; 65: S1237–S.
9. VAN DEN BERG R, DE HOOGE M, NAVARRO-COMPAN V *et al.*: Prevalence of structural lesions on MRI of the sacroiliac joints in patients with early axial spondyloarthritis and patients with back pain. *Arthritis Rheum* 2013; 65: S1238–S.
10. GONG Y, ZHENG N, CHEN SB *et al.*: Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis. *Arthritis Rheum* 2012; 64: 1399–406.
11. AYDIN SZ, MAKSYMOWYCH WP, BENNETT AN *et al.*: Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. *Ann Rheum Dis* 2012; 71: 56–60.
12. BENNETT AN, MCGONAGLE D, O'CONNOR P *et al.*: Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. *Arthritis Rheum* 2008; 58: 3413–8.
13. BISSON-VAIVRE A, ALCAIX D, ZARNITSKY C *et al.*: Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign. *Joint Bone Spine* 2013; 80: 280–6.
14. SIEPER J, VAN DER HEIJDE D, DOUGADOS M *et al.*: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis* 2013; 72: 815–22.
15. SIEPER J, LENAERTS J, WOLLENHAUPT J *et al.*: Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled IN-FAST study, Part 1. *Ann Rheum Dis* 2014; 73: 101–7.
16. LANDEWÉ R, BRAUN J, DEODHAR A *et al.*: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis* 2014; 73: 39–47.
17. DOUGADOS M, VAN DER HEIJDE D, SIEPER J *et al.*: Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol* 2014; 66: 2091–102.
18. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984; 27: 361–8.